XORTX Therapeutics Inc

자세한 내용은 XORTX Therapeutics Inc 회사

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

회사 정보

종목 코드 XRTX

회사 이름XORTX Therapeutics Inc

상장일Sep 30, 2015

CEODr. Allen W. Davidoff, Ph.D.

직원 수2

유형Ordinary Share

회계 연도 종료Sep 30

주소3710 - 33rd Street NW

도시CALGARY

증권 거래소TSX Venture Exchange (former Canadian Ventures Exchange)

국가Canada

우편 번호T2L 2M1

전화14034557727

웹사이트https://www.xortx.com/

종목 코드 XRTX

상장일Sep 30, 2015

CEODr. Allen W. Davidoff, Ph.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. James (Jim) Fairbairn

Chief Financial Officer

6.95K

+314.44%

Mr. Paul J. Van Damme

Independent Director

--

Dr. Stephen Haworth

Chief Medical Officer

--

Mr. William (Bill) Farley

Independent Director

--

Mr. Patrick Treanor

Independent Director

--

Dr. Allen W. Davidoff, Ph.D.

President, Chief Executive Officer, Director

--

Mr. Anthony J. Giovinazzo

Independent Non-Executive Chairman of the Board

--

Ms. Abigail Jenkins

Independent Director

--

Mr. Stacy Evans, M.D.

Chief Business Officer

--

Dr. Raymond Dennis (Ray) Pratt, M.D.

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. James (Jim) Fairbairn

Chief Financial Officer

6.95K

+314.44%

Mr. Paul J. Van Damme

Independent Director

--

Dr. Stephen Haworth

Chief Medical Officer

--

Mr. William (Bill) Farley

Independent Director

--

Mr. Patrick Treanor

Independent Director

--

Dr. Allen W. Davidoff, Ph.D.

President, Chief Executive Officer, Director

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Tue, Jul 15

주주

주주 유형

주주

비율

Davidoff, Allen Warren

3.18%

Giovinazzo (Anthony)

0.25%

Van Damme (Paul Joseph)

0.19%

Other

96.38%

주주

비율

Davidoff, Allen Warren

3.18%

Giovinazzo (Anthony)

0.25%

Van Damme (Paul Joseph)

0.19%

Other

96.38%

주주 유형

주주

비율

Individual Investor

3.41%

Other

96.59%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

17

129.44K

3.42%

-739.58K

2025Q1

20

127.29K

3.49%

-606.22K

2024Q4

21

385.20K

10.34%

-244.07K

2024Q3

22

287.39K

12.35%

-145.77K

2024Q2

20

276.67K

12.12%

-141.93K

2024Q1

21

272.84K

13.24%

-121.02K

2023Q4

19

553.49K

27.69%

+481.09K

2023Q3

20

176.53K

8.83%

-185.14K

2023Q2

19

179.60K

8.98%

-178.94K

2023Q1

18

180.91K

11.39%

-170.46K

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Davidoff, Allen Warren

112.26K

2.96%

+800.00

+0.72%

Jun 23, 2025

Giovinazzo (Anthony)

9.63K

0.25%

--

Apr 30, 2025

Van Damme (Paul Joseph)

7.11K

0.19%

--

Apr 30, 2025

Clearstead Advisors LLC

277.00

0.01%

--

Mar 31, 2025

National Bank of Canada

174.00

0%

-1.44K

-89.21%

Mar 31, 2025

Armistice Capital LLC

--

0%

-265.00K

-100.00%

Mar 31, 2025

UBS Financial Services, Inc.

--

0%

-17.43K

-100.00%

Mar 31, 2025

RBC Dominion Securities, Inc.

--

0%

-1.49K

-100.00%

Mar 31, 2025

Osaic Holdings, Inc.

--

0%

-1.15K

-100.00%

Mar 31, 2025

0.744USD

XORTX Therapeutics Inc

0.744

개요

회사

금융